Yung-Hung Luo1, Lei Luo2, Jason A Wampfler3, Yi Wang4, Dan Liu5, Yuh-Min Chen6, Alex A Adjei7, David E Midthun8, Ping Yang9. 1. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, MN, USA; Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, MN, USA; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 2. Department of Science and Education, Guizhou Province People's Hospital, Guiyang, Guizhou, China. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, MN, USA. 4. School of Public Health and Management, Wenzhou Medical University, University Town, Chashan, Wenzhou, Zhejiang, China. 5. Division of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. 6. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan. 7. Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, MN, USA. 8. Division of Pulmonary and Critical Care Medicine, Department of Health Sciences Research, Mayo Clinic, MN, USA. 9. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, MN, USA; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. Electronic address: yang.ping@mayo.edu.
Abstract
BACKGROUND: The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those who quit within the past 15 years. Our previous report found that two-thirds of newly diagnosed patients with lung cancer do not meet these criteria; they are reported to be either long-term quitters (≥15 years since quitting) or from a younger age group (age 50-54 years). We aimed to assess survival outcomes in these two subgroups. METHODS: For this prospective, observational cohort study we identified and followed up patients aged 50-80 years with lung cancer, with a smoking history of 30 pack-years or more, and included both current smokers and former smokers who quit within the past 30 years. We identified patients from two cohorts in the USA: a hospital cohort (Mayo Clinic, Rochester, MN) and a community cohort (Olmsted County, MN). Patients were divided into those meeting USPSTF criteria (USPSTF group) versus those not meeting USPSTF criteria (long-term quitters or the younger age group). The main outcome was overall survival at 5 years after diagnosis. 5-year overall survival was analysed with and without matching age and pack-years smoked for long-term quitters. The USPSTF group was subdivided into two age subgroups (55-69 years and 70-80 years) for multivariable regression analysis. FINDINGS: Between Jan 1, 1997, and Dec 31, 2017, 8739 patients with lung cancer were identified and followed up. Median follow-up was 6·5 (IQR 3·8-10·0) years, and median overall survival was 16·9 months (95% CI 16·2-17·5). 5-year overall survival was 27% (95% CI 25-30) in long-term quitters, 22% (19-25) in the younger age group, and 23% (22-24) in the USPSTF group. In both cohorts, 5-year overall survival did not differ significantly between long-term quitters and the USPSTF group (hospital cohort: hazard ratio [HR] 1·02 [95% CI 0·94-1·10]; p=0·72; community cohort: 0·97 [0·75-1·26]; p=0·82); matched analysis showed similar results in both cohorts. 5-year overall survival also did not differ significantly between the younger age group and the USPSTF group in both cohorts (hospital cohort: HR 1·16 [95% CI 0·98-1·38], p=0·08; community cohort: 1·16 [0·74-1·82]; p=0·52); multivariable regression analyses stratified by age group yielded similar findings. INTERPRETATION: Patients with lung cancer who quit 15 or more years before diagnosis and those who are up to 5 years younger than the age cutoff recommended for screening, but otherwise meet USPSTF criteria, have a similar risk of death to those individuals who meet all USPSTF criteria. Individuals in both subgroups could benefit from screening, as expansion of USPSTF screening criteria to include these subgroups could enable earlier detection of lung cancer and improved survival outcomes. FUNDING: National Institutes of Health and the Mayo Clinic Foundation.
BACKGROUND: The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those who quit within the past 15 years. Our previous report found that two-thirds of newly diagnosed patients with lung cancer do not meet these criteria; they are reported to be either long-term quitters (≥15 years since quitting) or from a younger age group (age 50-54 years). We aimed to assess survival outcomes in these two subgroups. METHODS: For this prospective, observational cohort study we identified and followed up patients aged 50-80 years with lung cancer, with a smoking history of 30 pack-years or more, and included both current smokers and former smokers who quit within the past 30 years. We identified patients from two cohorts in the USA: a hospital cohort (Mayo Clinic, Rochester, MN) and a community cohort (Olmsted County, MN). Patients were divided into those meeting USPSTF criteria (USPSTF group) versus those not meeting USPSTF criteria (long-term quitters or the younger age group). The main outcome was overall survival at 5 years after diagnosis. 5-year overall survival was analysed with and without matching age and pack-years smoked for long-term quitters. The USPSTF group was subdivided into two age subgroups (55-69 years and 70-80 years) for multivariable regression analysis. FINDINGS: Between Jan 1, 1997, and Dec 31, 2017, 8739 patients with lung cancer were identified and followed up. Median follow-up was 6·5 (IQR 3·8-10·0) years, and median overall survival was 16·9 months (95% CI 16·2-17·5). 5-year overall survival was 27% (95% CI 25-30) in long-term quitters, 22% (19-25) in the younger age group, and 23% (22-24) in the USPSTF group. In both cohorts, 5-year overall survival did not differ significantly between long-term quitters and the USPSTF group (hospital cohort: hazard ratio [HR] 1·02 [95% CI 0·94-1·10]; p=0·72; community cohort: 0·97 [0·75-1·26]; p=0·82); matched analysis showed similar results in both cohorts. 5-year overall survival also did not differ significantly between the younger age group and the USPSTF group in both cohorts (hospital cohort: HR 1·16 [95% CI 0·98-1·38], p=0·08; community cohort: 1·16 [0·74-1·82]; p=0·52); multivariable regression analyses stratified by age group yielded similar findings. INTERPRETATION:Patients with lung cancer who quit 15 or more years before diagnosis and those who are up to 5 years younger than the age cutoff recommended for screening, but otherwise meet USPSTF criteria, have a similar risk of death to those individuals who meet all USPSTF criteria. Individuals in both subgroups could benefit from screening, as expansion of USPSTF screening criteria to include these subgroups could enable earlier detection of lung cancer and improved survival outcomes. FUNDING: National Institutes of Health and the Mayo Clinic Foundation.
Authors: Michael T Jaklitsch; Francine L Jacobson; John H M Austin; John K Field; James R Jett; Shaf Keshavjee; Heber MacMahon; James L Mulshine; Reginald F Munden; Ravi Salgia; Gary M Strauss; Scott J Swanson; William D Travis; David J Sugarbaker Journal: J Thorac Cardiovasc Surg Date: 2012-07 Impact factor: 5.209
Authors: Samantha A Barry; Martin C Tammemagi; Sofiya Penek; Elisabeth C Kassan; Caroline S Dorfman; Thomas L Riley; John Commin; Kathryn L Taylor Journal: J Natl Cancer Inst Date: 2012-10-26 Impact factor: 13.506
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Zhifu Sun; Marie-Christine Aubry; Claude Deschamps; Randolph S Marks; Scott H Okuno; Brent A Williams; Hiroshi Sugimura; V Shane Pankratz; Ping Yang Journal: J Thorac Cardiovasc Surg Date: 2006-05 Impact factor: 5.209
Authors: John K Field; Robert A Smith; Denise R Aberle; Matthijs Oudkerk; David R Baldwin; David Yankelevitz; Jesper Holst Pedersen; Scott James Swanson; William D Travis; Ignacio I Wisbuba; Masayuki Noguchi; Jim L Mulshine Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Dandan Zhou; Jiemin Wang; Ke Yang; Liping Zhang; Quan Zheng; Jun Bai; Yaqiong Hu; Qingjie Mu; Chonggao Yin; Hongli Li Journal: Zhongguo Fei Ai Za Zhi Date: 2020-08-20